Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients

Background: The intent of this study was to explore the treatment efficacy of erlotinib, pemetrexed or docetaxel in individual patients with tumor EGFR wild-type pulmonary adenocarcinoma who failed previous chemotherapy. Methods: We retrospectively reviewed the clinical data of our EGFR wild-type pu...

Full description

Bibliographic Details
Main Authors: Yuh-Min Chen, Yung-Hung Luo, Chieh-Hung Wu, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang-Peng
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-03-01
Series:Journal of Cancer Research and Practice
Subjects:
adenocarcinoma
docetaxel
erlotinib
non-small-cell lung cancer
pemetrexed
Online Access:http://www.sciencedirect.com/science/article/pii/S2311300616300544

Internet

http://www.sciencedirect.com/science/article/pii/S2311300616300544

Similar Items